A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors

被引：0
|
作者：
Gupta, Sudeep
Jain, Minish Mahendra
Maru, Anish
Nag, Shona Milon
Somani, Naresh
Mehta, Ajay O.
Kulkarni, Sujay
Acharya, Shivani Anil
Dhobe, Poornima
Jadhav, Nitin
机构：
[1] Tata Mem Hosp, Bombay, Maharashtra, India
[2] Ruby Hall Clin, Pune, Maharashtra, India
[3] SEAROC Canc Ctr, Jaipur, Rajasthan, India
[4] Jehangir Clin Trials Dev Ctr, Pune, Maharashtra, India
[5] Bhagwan Mahaveer Canc Hosp & Res Ctr, Jaipur, Rajasthan, India
[6] Cent India Canc Res Inst, Nagpur, Maharashtra, India
[7] Piramal Healthcare Ltd, Bombay, Maharashtra, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3011
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I study of FOLFOX administered with flavopiridol (F) in patients with refractory solid tumors
    Dickson, M. A.
    Carvajal, R. D.
    Shah, M. A.
    Cane, L. M.
    Dials, H. J.
    Schwartz, G. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.
    Kim, Hyung-Don
    Yoo, Changhoon
    Ryu, Min-Hee
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors.
    Hong, D. S.
    Koetz, B. S.
    Kurzrock, R.
    Senzer, N. N.
    Hanekom, W.
    Naing, A.
    Wheler, J. J.
    Mink, J.
    Ren, M.
    Nemunaitis, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
    Minami, Hironobu
    Kawada, Kenji
    Ebi, Hiromichi
    Kitagawa, Koichi
    Kim, Yon-il
    Araki, Kazuhiro
    Mukai, Hirofumi
    Tahara, Makoto
    Nakajima, Hikaru
    Nakajima, Keiko
    CANCER SCIENCE, 2008, 99 (07): : 1492 - 1498
  • [45] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    Dees, E. Claire
    Infante, Jeffrey R.
    Cohen, Roger B.
    O'Neil, Bert H.
    Jones, Suzanne
    von Mehren, Margaret
    Danaee, Hadi
    Lee, Yih
    Ecsedy, Jeffrey
    Manfredi, Mark
    Galvin, Katherine
    Stringer, Bradley
    Liu, Hua
    Eton, Omar
    Fingert, Howard
    Burris, Howard
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 945 - 954
  • [46] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    E. Claire Dees
    Jeffrey R. Infante
    Roger B. Cohen
    Bert H. O’Neil
    Suzanne Jones
    Margaret von Mehren
    Hadi Danaee
    Yih Lee
    Jeffrey Ecsedy
    Mark Manfredi
    Katherine Galvin
    Bradley Stringer
    Hua Liu
    Omar Eton
    Howard Fingert
    Howard Burris
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 945 - 954
  • [47] A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177
    Chen, E. X.
    Hotte, S.
    Hirte, H.
    Siu, L. L.
    Lyons, J.
    Squires, M.
    Lovell, S.
    Turner, S.
    McIntosh, L.
    Seymour, L.
    BRITISH JOURNAL OF CANCER, 2014, 111 (12) : 2262 - 2267
  • [48] A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177
    E X Chen
    S Hotte
    H Hirte
    L L Siu
    J Lyons
    M Squires
    S Lovell
    S Turner
    L McIntosh
    L Seymour
    British Journal of Cancer, 2014, 111 : 2262 - 2267
  • [49] Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)
    Do, Khanh T.
    Chau, Nicole
    Wolanski, Andrew
    Beardslee, Brian
    Hassinger, Faith
    Bhushan, Ketki
    Pruitt-Thompson, Solida
    Scotton, Amber
    Frame, Sheelagh
    Zheleva, Daniella I.
    Blake, David
    Chiao, Judy
    Shapiro, Geoffrey I.
    CANCER RESEARCH, 2018, 78 (13)
  • [50] A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of a novel cyclin-dependent kinase inhibitor administered weekly in subjects with advanced malignancies
    Bannerji, Rajat
    Saltzman, Marc
    Rosenberg, Mitchell A.
    Small, Karen
    Black, Stuart
    Kirschmeier, Paul
    Statkevich, Paul
    Abutarif, Malaz
    Parry, David
    Yao, Siu-Long
    Nernunaitis, John
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3372S - 3373S
12345